Lomaira Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Lomaira (phentermine hydrochloride 8 mg) for weight management are increasingly reporting difficulty filling their prescriptions at local pharmacies. While Lomaira is not listed on the FDA or ASHP drug shortage databases as of early 2026, the practical availability challenges are real — and many prescribers are fielding calls and messages from frustrated patients who can't locate their medication. This guide is designed to help clinical teams understand the supply landscape, counsel patients effectively, and have a clear alternative medication strategy in place.

Current Supply Status of Lomaira (2026)

Lomaira is manufactured and distributed by KVK Tech, Inc. (Newtown, PA). As of early 2026, the medication is not on any FDA or ASHP shortage list, indicating no confirmed nationwide supply disruption. However, several structural factors create persistent localized availability gaps:

• Schedule IV status: DEA-regulated ordering limits, quota requirements, and secure storage obligations lead many pharmacies — especially high-volume chains — to minimize their phentermine controlled substance footprint.
• Brand-only 8 mg formulation: No FDA-approved generic for the 8 mg dose exists. Pharmacies must stock the Lomaira brand specifically, and those with historically low Lomaira prescription volume may not maintain standing inventory.
• Surging weight-loss prescription demand: Nationwide enrollment in weight-management programs has increased significantly, driven partly by the high-profile success of GLP-1 therapies. Phentermine-based medications are often prescribed as first-line or adjunctive agents, increasing demand broadly.

Clinical Considerations When Lomaira Is Unavailable

When a patient cannot locate Lomaira, prescribers have several options. Each carries clinical considerations:

1. Generic phentermine (15 mg, 30 mg, or 37.5 mg once daily)

Generic phentermine is widely available and dramatically less expensive (often $4–$10 for 30 tablets with GoodRx). The key pharmacologic difference is the delivery pattern: Lomaira's 8 mg TID regimen provides three distinct windows of appetite suppression, while 37.5 mg once daily delivers a larger bolus with a longer duration but no targeted meal-by-meal effect. Patients who chose Lomaira specifically for its meal-timed flexibility or to minimize stimulant side effects may notice a difference in tolerability. Consider recommending 37.5 mg once-daily as a bridge only, with a plan to return to Lomaira when available, if clinically appropriate.

2. Qsymia (phentermine/topiramate ER)

Qsymia may be appropriate for patients seeking a transition to a long-term FDA-approved option. It contains phentermine (at doses ranging from 3.75 mg to 15 mg) combined with extended-release topiramate. Qsymia has demonstrated superior weight loss to phentermine alone. Note that it is also a Schedule IV CIV controlled substance and requires REMS enrollment. Contraindicated in pregnancy — appropriate contraception counseling and pregnancy testing is required. Topiramate carries teratogenic risks (craniofacial birth defects).

3. Contrave (naltrexone/bupropion)

Contrave is a non-stimulant, non-controlled weight-loss option approved for chronic weight management. It's appropriate for patients with contraindications to stimulants (e.g., uncontrolled hypertension, arrhythmia, anxiety disorders, substance-use history). It is not appropriate for patients currently taking opioids or with seizure disorders. Black box warning for suicidal thoughts and behaviors (bupropion component).

4. GLP-1 receptor agonists

If a patient's clinical profile supports it (BMI ≥30 or ≥27 with comorbidities, no contraindications), a transition to a GLP-1 receptor agonist may provide more durable, larger-magnitude weight loss. Note that availability of GLP-1 medications (Wegovy, Zepbound) has had its own challenges, and the cost burden is significantly higher without insurance coverage.

Counseling Patients About Lomaira Availability Challenges

When counseling patients experiencing difficulty filling Lomaira, consider sharing these evidence-based strategies:

• Have them call pharmacies specifically asking for "Lomaira brand phentermine hydrochloride 8 mg by KVK Tech" — not just generic phentermine
• Ask pharmacies to special-order it — most can within 1–2 business days if they have a DEA license
• Try independent pharmacies, which have more ordering flexibility than chains
• Use medfinder — a paid service that contacts pharmacies on the patient's behalf and texts results, saving significant time
• Fill mid-month on a Tuesday–Thursday for best controlled substance availability

Prescribing Tips to Reduce Dispensing Friction

• Write prescriptions for 90-day supplies where legally permitted in your state — fewer refills means fewer trips locating stock
• Direct the prescription to a pharmacy you know carries Lomaira routinely (many obesity medicine specialists maintain a short list of preferred pharmacies for difficult-to-fill products)
• Consider indicating a DAW (Dispense As Written) vs. generic substitution preference clearly, since there is currently no generic 8 mg equivalent — this eliminates pharmacist confusion

How medfinder Supports Your Patients

medfinder is a paid concierge service that contacts pharmacies on behalf of your patients to locate in-stock medications. For patients with Lomaira fill difficulties, you can recommend medfinder.com/providers as a resource to share with your clinical team and patients. The service covers all medications, not just shortage drugs.

For the patient-facing version of this guide, see: Lomaira shortage update: what patients need to know in 2026